Introduction
The global incidence of cutaneous melanoma is constantly rising, and in the USA alone 76 380 persons were estimated to be diagnosed with this disease in 2016, with 10 130 estimated to succumb to it [1] . The American Joint Committee on Cancer classifies patients with melanoma into four stages. Stages IA-IIC include patients with thinner or thicker melanoma confined to the skin, stage III patients have a regional disease spread defined by a lymphatic node or other lymphatic metastasis (satellite lesions, in-transit metastasis), and stage IV included patients presenting with disseminated disease [2] . Primary tumor thickness (T) is strongly associated with the risk for disease relapse, and 10-year survival ranges from 92% in T1 (≤ 1.00 mm) melanomas to 80% in T2 (1.01-2.00 mm), 63% in T3 (2.01-4.00 mm), and 50% in T4 patients with melanomas thicker than 4.00 mm. Sentinel lymph node (SLN) mapping is commonly offered to patients with T2-T4 localized tumors and to patients with 'higher-risk' T1 melanomas (with adverse clinical features such as ulceration or high mitotic rate) who bear a risk for relapse that exceeds 10%. The SLN status is the most important prognostic factor for patients with localized melanoma, which is based on the extent and number of nodes involved. In microscopic (stage IIIA-IIIB) or gross (stage IIIB-IIIC) melanoma, the risk for disease recurrence ranges from around 35% to more than 89%, and the consecutive 5-year survival drops from 75% to around 50% [2, 3] .
The SLN is defined as the first lymph node in the regional lymphatic basin that receives drainage from the primary tumor, potentially being the first site of malignant cell metastasis (two or more SLNs can be present depending on the site of the primary tumor). The technique of SLN mapping was best described by Morton et al. [4] who led the field in its application in melanoma staging. There are at least two benefits to identifying the SLN: (a) improved accuracy of nodal staging by examining multiple sections of the SLN for micrometastases using immunohistochemistry (IHC for S100, MART-1, HMB45, and tyrosinase) in addition to routine hematoxylin and eosin (H&E) staining [5] and (b) negating the need for a complete node dissection for staging purposes in patients who do not have clinically identified regional node involvement when a non-involved SLN is identified. Nevertheless, in an updated analysis of MSLT-I, the biggest clinical trial comparing SLN mapping to observation, even though the SLN biopsy dropped the 10-year hazard ratio (HR) for disease-free survival especially in intermediate-thickness melanomas (defined as Breslow 1.2-3.5 vs. > 3.5 mm for thick melanomas), there was no impact on 10-year melanoma-specific survival rate either for intermediate (HR: 0.84; 95% confidence interval: 0.64-1.09; P = 0.18) or for thick melanomas (HR: 1.12; 95% confidence interval: 0.76-1.67; P = 0.56) [6] .
At the molecular level, a common pattern in cancer progression is metastatic involvement of the regional lymph node [7] potentially serving as a bridgehead for further metastatic spread [7] . Among patients with SLN + and SLN − melanoma, prognosis varies and benefits of adjuvant interferon (IFN)-α2b, pegylated IFN, and ipilimumab are confined to a subset [8, 9] . The SLNs can be invaluable for understanding the host-tumor interaction. The known down regulation of immune activity in lymph nodes proximal to the primary tumor indicates that the SLN is likely to be immunologically modulated to a greater extent than remote regional lymph nodes [10] . Molecular characterization of positive and negative SLNs through gene expression profiling may improve the understanding of mechanisms of metastasis and immune evasion and identify gene signatures of SLN
− that correlate with diagnosis and clinical outcome.
In this prospective study, we molecularly characterized the regional nodal status of positive and negative SLNs in patients with a recent diagnosis of cutaneous melanoma. The main goal of our analysis was to search for significantly differentially expressed genes that are associated with sentinel lymph node status. Our analysis identified a 25-gene signature, consistent with metastatic melanoma and reflective of its microenvironment at the SLN level.
Patients and methods

Patients
Patients were eligible if they were at least 12 years of age, had primary melanoma with Breslow thickness more than or equal to 2.01 mm (T3 or T4, without or with ulceration), and underwent an SLN biopsy as a standardof-care staging procedure. All participants signed a written informed consent form. The study was conducted at the University of Pittsburgh Cancer Institute in accordance with Good Clinical Practices, local regulatory requirements, and Declaration of Helsinki. The study and the informed consent forms were approved by the IRB of the University of Pittsburgh.
Laboratory and statistical methods
Study endpoints
Our main goal for this study was to properly collect and process SLN material of melanoma patients to explore the different potential molecular features of the tumor microenvironment. The primary objective was to perform a gene profiling analysis to molecularly characterize the regional nodal status of positive and negative SLNs in patients undergoing SLN mapping and dissection for routine staging of melanoma (primary endpoint: mRNA expression by gene array). Secondary objectives included investigation of an association between specific gene signatures for positive and negative SLNs and clinical outcomes (e.g. recurrence and survival). Because of the relatively short follow-up period, analysis of the secondary objectives could not be completed.
Sentinel lymph node tissue procurement
Surgically resected SLNs were dissected and, if sized over 8 mm in its longest diameter, the peripheral parts were stained for H&E and no more than 20% of the tissue was immediately placed in RNA lysis buffer (Qiagen RNeasy kit; Qiagen Inc., Valencia, California, USA) and frozen at − 80°C for future mRNA extraction for gene expression profiling. The rest of the LN was placed in 10% formalin buffer and sent for central reviewing along with the H&E sections. SLN positivity was assessed by H&E and immunohistochemistry (MART-1/melena-A, gp100, tyrosinase, S100 staining). Patients were pathologically characterized as SLN + / SLN − . The tissue was not used for research until the pathology report established a final diagnosis. A schematic of the study procedure can be viewed in Fig. 1 . mRNA expression assays: eukaryotic target preparation and hybridization Total RNA was extracted from 24 negative and 24 positive, fresh-frozen SLNs using the Qiagen miRNeasy kit (Qiagen Inc.), according to the manufacturer's protocol. Only total RNA of high quality and integrity was subjected to further processing after purification, defined as 260/280 absorption ratio more than 1.8 on spectrophotometry using the NanoDrop 1000 (NanoDrop, Wilmington, Delaware, USA) and an RIN value more than 8.0 on electrophoretic analysis using the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, California, USA). In-vitro transcription was performed using the Ambion MessageAmp Premier Enhanced assay protocol (Ambion Inc., Austin, Texas, USA) starting with 500 ng of purified total RNA. Confirmation of cRNA diversity was obtained using the Bioanalyzer 2100 to generate an electrophoretogram for each IVT reaction regarding sample yield, integrity, and size diversity against a Universal Human Reference RNA (Stratagene, La Jolla, California, USA). Fifteen micrograms of purified, amplified, and biotin-labeled cRNA was fragmented and hybridized onto Affymetrix Human Genome HGU133A 2.0 arrays (Affymetrix Corp., Santa Clara, California, USA) for 18 h. Washing, staining, and scanning of arrays were performed on the Affymetrix Fluidics Station 450 and Scanner 3000 immediately after completion of hybridization.
Data analysis
Microarray data were processed by means of RMA express software [11] [12] [13] . The gene expression level between the SLN + and SLN − groups was compared using the Significance analysis of microarrays (SAM) implemented in R [14] and the false discovery rate was controlled at 5%. We considered probe sets with fold change more than 1.5 and q value less than 0.05 as differentially expressed. Heatmap presentation of the gene expression level between the SLN + and SLN − groups for the differentially expressed genes was provided. Pathway analysis of the differentially expressed gene list was performed using the Ingenuity Pathways Analysis software (Ingenuity Systems, Redwood city, California, USA). The Benjamini and Hochberg method was used to adjust for multiple testing in the pathway analysis.
Results
Patients
A total of 48 patients were enrolled between February 2009 and August 2013 and all had primary cutaneous melanoma of Breslow thickness more than or equal to 2.01 mm (T3 or T4) without (N = 19) or with (N = 29) ulceration. Half of the patients had an SLN involved by melanoma metastasis as assessed by H&E and immunohistochemistry (MART-1/melena-A, gp100, tyrosinase, S100 staining). Table 1 summarizes the patient demographics and disease characteristics. Markers analyzed with SAM with a fold change of at least 1.5 and a q value of less than 0.05 were considered to be differentially expressed. A total of 89 probe sets (73 genes) were identified as having significantly different expression between SLN Figure 2 shows the heatmap of the 89 probe sets for genes that were differentially expressed at significant levels (1.5-27-fold; q < 0.05). Gene enrichment analysis of top differentially expressed genes was conducted using the Ingenuity Pathways Analysis program. Of the 73 originally identified transcripts, 25 achieved differential expression of highest statistical significance and were common among the top (most significant) pathways, allowing us to establish a gene signature consistent with melanoma and its microenvironment at the SLN. Figure 3 shows the heatmap of the 25 genes. These genes are described in Table 2 . The top canonical pathways, in order of statistical significance according to adjusted P value, were associated with the mitotic roles of the polo-like kinases (KIF23, CDC20, PRC1, CCNB2, CDK1, KIF11, and CCNB1), DNA damage-induced 14-3-3 sigma signaling (CCNE2, CCNB2, CDK1, and CCNB1) and G2M DNA damage checkpoint regulation (TOP2A, CCNB2, CDK1, CHEK1, and CCNB1), cyclins and cell cycle regulation (cyclins A2, B1, B2, E2, and CDK1), eumelanin biosynthesis (TYR and DCT) and melanocyte development and pigmentation signaling (TYRP1, TYR, DCT, SOX10), the role of CHK proteins in cell cycle checkpoint control (CDK1, CHEK1, and RCF3), the antiproliferative role of TOB in T-cell signaling (CCNA2 and CCNE2), and p53 signaling (BIRC5, CHEK1, and SERPINE2). Table 3 lists the top pathways and the corresponding level of significance.
Discussion
Our study sought to identify genes that are differentially expressed in the SLN microenvironment of patients who undergo lymphatic mapping for melanoma staging in the presence or absence of micrometastatic disease. Twenty five genes that achieved differential expression of highest statistical significance were found to be common among the most significant pathways. The major canonical pathways were implicated in immunosuppression, melanoma carcinogenesis, and metastatsis. Further study of this signature and related pathways may illuminate the understanding of mechanisms of metastasis and immune evasion and may correlate with diagnosis and clinical outcome.
The top canonical pathways represented the mitotic roles of the polo-like kinases (KIF23, CDC20, PRC1, CCNB2, CDK1, KIF11, and CCNB1) involving key regulators of the cell cycle and regulators of several different aspects of mitosis, providing important insights into the process of oncogenesis [15] . The next top pathways were also closely linked with several overlapping differentially expressed genes, including DNA damage-induced 14-3-3 sigma signaling (CCNE2, CCNB2, CDK1, and CCNB1), that play a critical role in DNA damage-induced checkpoints by controlling the biological activity of several key cell cycle checkpoint proteins [16] . Next were G2M DNA damage checkpoint regulation (TOP2A, CCNB2, CDK1, CHEK1, and CCNB1), cyclins and cell cycle regulation (cyclins A2, B1, B2, E2, and CDK1), and p53 signaling (BIRC5, CHEK1, and SERPINE2) involving key components of cell cycle regulation and tumor suppression. In fact, melanoma harbors one of the highest DNA genomic instability ratios, and increased expression of CHEK1 among other checkpoint/repair pathway genes is associated with carcinogenesis and metastasis [17] . Similarly, the identified linked and overlapping pathways included the role of CHK proteins in cell cycle checkpoint control (CDK1, CHEK1, and RCF3) and the antiproliferative role of TOB in T-cell signaling (CCNA2 and CCNE2). Finally, as expected, significant pathways also included eumelanin biosynthesis (TYR and DCT) and melanocyte development and pigmentation signaling (TYRP1, TYR, DCT, SOX10) implicated in melanogenesis. KIF11 and KIF23 code for kinesin 5 (EG5) and kinesin 6 (MKLP1). These are members of a superfamily that is required for duplicate centrosome separation, bipolar mitotic spindle formation, and chromosome movement during mitosis. Overexpression occurs in many highly proliferative cancers. Investigation into EG5 inhibition as anticancer treatment was extensive, but results for melanoma treatment among other malignancies have been disappointing to date [18] . MCM4 belongs to the mini-chromosome maintenance (MCM) proteins family. It is a key member of the prereplication complex that performs helicase activity for DNA unwinding and subsequent replication, and its function is regulated by the S-phase checkpoint inhibitors [19] . Molecular studies suggest increased levels in multiple precancerous lesions and malignancies [19] . For melanoma, increased expression of MCM4 correlates with increased tumor thickness, shorter distantmetastasis-free survival and overall survival, and poor clinical outcome [20] . CDC20 is a mitotic coactivator of the anaphase-promoting complex/cyclosome (APC/C), and its main role is promoting the initiation of anaphasis and chromosome separation through ubiquination of anaphase inhibitors. CDC20 overexpression has been documented in many cancers and is reported to inversely correlate with p53 function [21] . CDC6 is a member of the prereplicative complex and is required for DNA loading with MCM protein as an essential step in the initiation of DNA synthesis. It is tightly regulated and inactivated by CDK1 after the onset of S-phase in order to prevent rereplication. Overexpression is common in carcinogenesis as it promotes DNA hyper-replication and represses the p15
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(INK4/ARF locus) as well as E-cadherin to promote epithelial-to-mesenchymal transition -a key event in the process of metastasis [22] . This is evident through the observation of CDC6 higher expression in melanoma metastatic lesions when compared with the primary tumor [23] . PRC1 is a 'nonmotor' protein participating in the formation of the mitotic spindle. It interacts with several 'motor' proteins like MKLP1, regulating their expression and function. It is also required for spindle localization of the Aurora A kinase, another vital protein for centrosome maturation and spindle assembly. Overexpression in cancer highly correlates with chromosomal instability [24] . BIRC5 (survivin) is an inhibitor of apoptosis; it promotes cell cycle progression and has been correlated to tumor recurrence and chemotherapy resistance in many tumors. Survivin plays a role in melanomagenesis, and its expression in SLNs has been reported to be inversely correlated with disease progression and survival in stage III melanoma patients [25] . Cyclin A2 (CCNA2) is a key regulator of both S/M phases during the cell cycle. Heatmap of the probe sets for 25 genes that were significantly differentially expressed between sentinel lymph nodes (SLN) involved by melanoma (+ ) compared with SLN − and belonged to the top (most significant) canonical pathways.
CCNA2 upregulation is a common event in cancer and has been shown to correlate with tumor thickness, cell proliferation rate, progression, and survival, particularly in superficially spreading melanomas [26] . Cyclin B2 (CCNB2) is also involved in the G2/M-phase transition, and its tumor overexpression or elevated circulating mRNA levels are associated with dismal outcome in many tumors [27] . CCNE2 along with CCNE1 is necessary for the formation of the prereplication complexes on DNA in order for the cells to leave the quiescent state and enter the cell cycle. They also promote the G1/S-phase transition through retinoblastoma phosphorylation and centrosome duplication. Data from breast cancer suggest that CCNE2 is not related to proliferation but instead with other oncogenic attributes such as invasion and drug resistance and is independently associated with early metastases and poor survival [28] . CDK1 regulates through sequential binding to CCNA and CCNB1, the cell cycle transition from late S-phase, and is required for entry into mitosis. CDK1 overexpression is prominent in primary invasive and metastatic melanoma lesions [23] . CHEK1 is a part of the DNA damage checkpoint-regulating machinery and is mainly sensitive for single-strand DNA breaks. Upon detection, it arrests cell cycles in late S-phase or G2/M transition, allowing damage restoration. It also confers resistance to DNA-damaging therapies (e.g. alkylating agents, radiation). Because other checkpoints like p53 are defective in melanoma, efforts are made to inhibit CHEK1 either alone or in combination with DNA-damaging agents to induce apoptosis in many tumor types [29] . DCT or tyrosinase-related protein 2 belongs to the melanin production-associated genes, and expression is consistent across all stages of melanoma. It confers resistance to apoptosis either from oxidative stress or from drugs like cisplatin or radiation therapy [30] . RFC3 is one of five replication factor subunits that form a multiprotein complex known as activator 1, which acts as a clamp loader of the proliferating cell nuclear antigen onto primed DNA. proliferating cell nuclear antigen is required for processive DNA chain elongation during synthesis [31] . RFC3 is overexpressed in many cancers, mainly of endothelial origin, correlates with dismal disease survival, and associates with the mitogenic transcription factor MYC -a known oncogene in melanoma vertical growth phase and metastasis [31] . RRM2 is the key regulatory component of ribonucleotide reductase, an enzyme responsible for deoxyribonucleotide triphosphate production during synthesis. RRM2 downregulation is both necessary and sufficient for the establishment and maintenance of senescence-associated cell growth arrest. In BRAF or NRAS mutated nevi, RRM2 may overcome oncogenic BRAF-induced or NRAS-induced senescence. Further, in melanoma patients with BRAF or NRAS mutant melanoma, high RRM2 expression correlates with poor overall survival [32] . SerpinE2 (protease nexin-1) belongs to the serpin protein superfamily and acts as a protease inhibitor mainly for thrombin, plasmin, and plasminogen activators, all factors associated with tissue remodeling. Although theoretically its ability to reduce proteolysis and extracellular matrix degradation would protect against cancer cell invasion and metastasis, serpinE2 overexpression leads to upregulation of matrixmetalloproteinase 9, which cleaves serpinE2 to allow protease-mediated remodeling [33] . SerpinE2 is highly upregulated upon MAPK pathway stimulation; its overexpression is common in many cancers with such pathway oncogenic alterations. SOX10 is an essential factor for specification, survival, and differentiation of neural crestderived lineages including melanocytes. It controls both melanogenesis and melanocyte survival and plays a role in cell cycle progression through microphthalmia-associated transcription factor regulation, whereas SOX10 ablation leads to G1 cell cycle arrest as well as promoting [34] melanoma cell invasion and metastasis [34, 35] . TOP2A is a group of highly conserved enzymes that catalyze the ATP-dependent transport of one intact DNA double helix through another during replication and chromosome Gene expression in melanoma SLN Tarhini et al. 435 segregation. It belongs to the DNA defect repair gene group, and overexpression or aberrant function regulation is associated with chromosome instability. TOP2A has been extensively studied in melanoma; its expression correlates with tumor thickness and with risk for recurrence, metastasis, and resistance to alkylating chemotherapeutic agents and is considered an independent prognostic factor of poor clinical outcome [17] . TTK (or monopolar spindle 1), kinase has an essential role in the spindle assembly checkpoint preventing cell cycle progression from the metaphase to the anaphase when chromosomes are improperly attached to the mitotic spindle. This is crucial for survival of aneuploid cells, especially in the presence of other checkpoint-deficient mechanisms like TP53, and correlates with high tumor grade and resistance to antimitotic agents [36] . Tyrosinase is the principal enzyme in the process of melaninogenesis. This enzyme is expressed in all stages of melanoma development, and some reports suggest that the percentage of positivity slightly drops in metastatic disease [37] . It is one of the four standard markers for melanoma diagnosis using IHC, and detection is highly specific for melanoma disease. TYRP1 appears to have a less prominent role in melaninogenesis but acts more as a tyrosinase activity regulator and protector of melanocytes against oxidative stress; further, apoptosis in regionally involved LNs has been correlated with shorter relapse-free survival and dismal outcome in stage III melanoma patients [38] .
An interesting observation in our analysis has been the implication of a number of differentially expressed genes in the regulation of host immunity toward melanoma, including CCL20, SGK1, CCNB1, and TYM S. CCL20 is a strong chemotactic cytokine for CCR6 + -expressing memory lymphocytes and plasmatoid dendritic cells. This is potentially an early event in melanoma development, and melanoma tumors that produce CCL20 attract plasmatoid dendritic cells, which may initiate a specific antitumor response [39] . SGK1 belongs to the AGC kinase family and is a downstream effector of the PI3K pathway. Its function is regulated through posttranslational modifications by the mTOR complex. Besides its role in homeostasis through membrane regulation of Na + /K + turnover, SGK1 promotes oncogenesis by phosphorylating the tumor suppressing gene p27 and activates murine double-minute homolog 2-dependent p53 ubiquitination, which affects cell cycle checkpoint arrest and apoptosis [40] and shifts immune response toward TH2 differentiation, inhibiting IFN-γ mediated tumor rejection [41] . CCNB1 regulates mitotic spindle assembly during G2/M phases, and under normal conditions its expression remains nuclear at very low levels, whereas in cancer cells it is overexpressed, residing in the cytoplasm, a phenomenon attributed to p53 dysfunction. In addition, CCNB1 has been long identified as a tumor antigen and can elicit specific T and B-cell antitumor responses [42] . TYM S is a crucial enzyme for DNA synthesis and catalyzes the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate. Overexpression is a common finding in melanoma, primary or metastatic, and may have an adverse effect in immune therapies [43] .
Early efforts in molecularly defining metastatic disease present in SLNs that cannot be detected by conventional pathology used the same markers as with IHC staining, trying to identify microscopic disease that could not be revealed by classic pathological examination. A median yield of 13-52% of additionally identified 'molecular SLN metastasis' often correlated with clinical outcome (reduced relapse-free and overall survival) but never made it to the clinic to be incorporated in diagnostic/ prognostic criteria [44, 45] . Even after CLND, postoperative lymphatic drainage of affected areas with persistent expression of melanoma differentiation genes seems to be prognostic of early relapse [46] . Establishing a 'gene expression signature' that can predict recurrence risk and/or treatment response is rational. Many researchers looked into primary tumor gene expression profiles. Among them, Winnepenninckx et al. [20] retrospectively evaluated 83 primary melanoma tumors and established a 254-gene signature associated with distantmetastasis-free survival in 58 patients. A following report that included 60 patients' updated follow-up of at least 4 years concluded that the most important pathways in predicting distant-metastasis-free survival are those associated with DNA repair and specifically with S-phase checkpoint and postreplicative DNA repair mechanisms, an observation consistent with our results.
Conway et al. [47] identified osteopontin expression as the most significant predictor of relapse-free survival in a cohort of 254 primary melanomas (≥0.75 mm thick) before and after adjustment for other risk factors. Validation in a second cohort of 218 patients also correlated osteopontin expression with reduced relapse-free survival and higher probability of SLN involvement. Additional genes that closely correlated to osteopontin and with the most significant difference between relapsers and nonrelapsers included BIRC5, TOP2A, CCNA2, TK1, and RAD51, which is also consistent with our results [47] . Efforts made to investigate gene expression inside SLNs are more recent. Koh et al. [48] tried to define a distinct expression profile of genes between primary melanoma and metastatic SLNs, evaluating 10 primary and nine SLN lesions, although only four of them were paired (same patient). Most of the patients had documented systematic disease at the time of diagnosis. Of the 174 genes upregulated in the SLN, those with the biggest fold difference correlated with the host's immune response, like tumor antigens (MAGE family antigens) and FC-like receptors [48] . Torisu-Itakura et al. ) and show that the SLN microenvironment is affected by melanoma even in the absence of actual disease [49] .
To date, assessment of the risk for relapse in patients with localized melanoma is based solely on surgical and pathologic criteria like Breslow thickness, ulceration, lymphatic involvement, and mitotic rate. The SLN status remains the most important prognostic factor. The pathological examination of SLN uses IHC antibodies for tumor cell staining (S100, MART-1, HMB45, tyrosinase) or classic H&E stains. This approach is inherently limited because microscopic tumor foci can be missed in the midsection parts of the examined SLN. On the contrary, pursuing genes expressed in the tumor microenvironment may overcome this obstacle [50] . In uveal melanoma, a gene expression profile (GEP) assay stratifying this subset of melanomas according to the risk for metastasis as predicted by a 15-gene signature is increasingly used to guide patients' treatment [51] . Gerami et al. [52] tried to expand GEP in an effort to predict risk recurrence in stage I and II patients with cutaneous melanoma. He developed a 27-gene signature and evaluated archived FFPE primary melanomas from 220 patients with at least 5 years of follow-up (less if a metastatic event was evident). In 119 stage I patients, negative prognostic value (NPV) and positive prognostic value (PPV) (i.e. cases labeled class 1 and class 2, indicating no risk and risk for metastasis, respectively) were 95 and 56% respectively, whereas for 109 stage II patients (45 stage IIA, 42 stage IIB, and 14 stage IIC) NPV and PPV were 67/90%, 43/96%, and 33/100%, respectively, indicating that increasing Breslow thickness led to a higher 'false' prediction of relapse [52] . The same group compared the prognostic value of SLN status with that of the expanded GEP. The results showed that the SLN status had a greater PPV for distant metastasis (55 vs. 50%), but a less-NPV (67 vs. 82%). Disease-free survival (DFS) and distant-metastasis-free survival (DMFS) were similar for SLN + , GEP class two patients, and for patients with SLN − but classified as GEP class 2. DFS and DMFS varied from 79 and 82% for GEP class 1 to 55 and 64% for SLN − patients, indicating a higher impact of GEP in predicting 'less-aggressive' disease. Thus, for nine patients with SLN + but GEP 1 score, DFS and DMFS were intermediate (53% for both) [53] .
Previous studies mostly retrospectively investigated archived formalin-embedded primary lesions. This approach had the caveat of RNA degradation during fixation and storage. Diversity in the populations examined (thin/thick melanomas, clinical staged tumors, and stage IV tumors at diagnosis) and lack of quantitative validation make these results difficult to interpret. Common candidate genes are generally different within studies, adding to these limitations. Our results include most of the pathways implicated in previous studies linking melanoma progression to higher expression of genes correlating to DNA replication, repair, and checkpoint inhibitor pathways. To our knowledge, this is the first molecular prospective study of a homogenous patient population based on Breslow thickness evaluating SLN microenvironment molecular status and clinical data, along with estimated risk for relapse; response to adjuvant treatment will be reported upon maturation.
Conclusion
In our investigation of the SLN microenvironment, a 25-gene signature is significantly differentially expressed between the SLN + and SLN − groups. These genes are related to melanoma oncogenesis and to immunosuppression. The expression profile provides a signature of nodal involvement and warrants further investigation toward understanding the mechanisms of melanoma metastasis in relation to melanoma metastasis diagnosis. Association with clinical outcome will be investigated as follow-up of our patient cohort matures.
